Doximity, Inc.

Valuation Analysis

About the Company

Doximity, Inc. en bref

Doximity, Inc. (DOCS) is currently trading at 17,84 € with a market capitalization of 3,3 Md €. The trailing P/E ratio stands at 20.86x, with a forward P/E of 12.8x. The 52-week range spans from 14,97 € to 66,77 €; the current price is 73.3% below the yearly high. Year-over-year revenue growth stands at +5.1%. The net profit margin stands at 30.4%.

💰 Dividende

Doximity, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

19 analystes évaluent Doximity, Inc. (DOCS) au consensus : Acheter. L'objectif de cours moyen est de 22,18 €, soit un potentiel de +24.37% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 15,71 € à 36,65 €.

Doximity, Inc. : la thèse d'investissement en détail

Doximity, Inc. (DOCS) operates in the Healthcare — specifically Health Information Services — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

With a gross margin near 89.09%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Free cash flow is positive and net margins stand at 30.4%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions. Wall Street consensus sits at Buy with an average price target implying roughly 24.37% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Short interest sits at 12.7% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valorisation en contexte

With a PEG ratio of 0.59, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

À surveiller

• The forward P/E of 12.8x is meaningfully below the trailing 20.86x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 24.37% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to market-like volatility, elevated short interest (12.7%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Doximity, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.